Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTONE versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTONE versus TRIACORT.
HYDROCORTONE vs TRIACORT
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
Adrenocortical insufficiencyAllergic reactionsCollagen diseasesDermatologic diseasesEndocrine disordersGastrointestinal diseasesHematologic disordersNeoplastic diseasesNervous system conditionsOphthalmic diseasesRenal diseasesRespiratory diseasesRheumatic disordersSarcoidosisSystemic lupus erythematosus
Allergic conditionsDermatologic diseasesEndocrine disordersGastrointestinal diseasesHematologic disordersNeoplastic diseasesNervous system disordersOphthalmic diseasesRenal diseasesRespiratory diseasesRheumatic disorders
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
10-20 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Hepatic via CYP3A4 and other microsomal enzymes; primarily metabolized by 11-beta-hydroxysteroid dehydrogenase and 5-alpha-reductase.
Hepatic via CYP3A4; metabolites are inactive.
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
~90% bound to corticosteroid-binding globulin (CBG) and albumin.
Approximately 78% bound to corticosteroid-binding globulin (CBG) and albumin. Binding is saturable at higher concentrations.
0.3–0.5 L/kg; distributes widely into tissues, with high penetration into CSF.
1.4 ± 0.5 L/kg. This large Vd indicates extensive extravascular distribution, reflecting high tissue penetration and sequestration in adipose tissue.
Oral: ~96% (rapid and complete); IM: 100% (by definition).
Oral: 80-90% (well-absorbed with minimal first-pass metabolism); Intramuscular: 100% (assuming correct administration).
No dose adjustment required for renal impairment. Not removed by hemodialysis.
No adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, reduce dose by 50%; for GFR <10 mL/min, avoid use
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 60% or consider alternative.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Adrenal insufficiency: oral 8-10 mg/m²/day in 3 divided doses; IV/IM: 1-2 mg/kg/dose every 6-8 hours. Status asthmaticus: IV 4-8 mg/kg/day divided every 6 hours.
0.5-1 mg/kg orally once daily, max 20 mg/day
Start at lowest effective dose (e.g., 10-15 mg/day oral). Monitor for hyperglycemia, hypertension, osteoporosis. Use lower initial doses due to increased risk of adverse effects.
Initiate at 5 mg orally once daily; titrate cautiously due to increased risk of adverse effects
None
Corticosteroids may cause immunosuppression, increasing susceptibility to infections. Avoid live vaccines in patients on high-dose therapy.
Adrenal suppression, increased susceptibility to infections, masking of infection, Cushing's syndrome, osteoporosis, cataracts, glaucoma, hypertension, hypokalemia, growth retardation in children, and neuropsychiatric effects.
["Immunosuppression and increased infection risk","Adrenal suppression with prolonged use","Osteoporosis risk with long-term use","Growth suppression in children","Cushing's syndrome with prolonged use","Exacerbation of fungal infections"]
Systemic fungal infections, administration of live virus vaccines, idiopathic thrombocytopenic purpura (IM use), hypersensitivity to hydrocortisone.
["Systemic fungal infection","Hypersensitivity to any component","Administration of live or live-attenuated vaccines in immunocompromised patients"]
Data Pending Review
Data Pending Review
Avoid excessive grapefruit juice as it may increase hydrocortisone levels. Limit sodium intake to manage fluid retention and hypertension. Maintain adequate potassium intake (e.g., bananas, oranges) to counteract hypokalemia. No significant interaction with alcohol but it may exacerbate GI irritation.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing TRIACORT levels. Limit high-sodium foods to reduce fluid retention. Maintain adequate potassium intake (bananas, oranges, spinach) to counteract hypokalemia. Alcohol may increase gastric irritation.
Corticosteroids including HYDROCORTONE are associated with a small increased risk of cleft palate (first trimester), fetal growth restriction, and adrenal suppression in neonates with prolonged maternal use. Second/third trimester use may cause fetal adrenal suppression but no specific malformation pattern. Risk must be weighed against maternal benefit.
FDA Pregnancy Category C. First trimester: associated with increased risk of cleft palate (odds ratio ~3.4). Second/third trimester: increased risk of intrauterine growth restriction, oligohydramnios, and fetal adrenal suppression. Chronic use may cause neonatal adrenal insufficiency. Human data limited; animal studies show teratogenicity.
HYDROCORTONE is excreted into breast milk in low concentrations. M/P ratio is approximately 0.25 for hydrocortisone. Doses up to 40 mg daily are considered compatible with breastfeeding; higher doses may require monitoring for infant adrenal suppression. Use lowest effective dose.
Incompatible with breastfeeding. Corticosteroids are excreted in breast milk; M/P ratio approximately 0.5. Potential for growth suppression and endogenous cortisol suppression in the infant. Avoid use or discontinue nursing.
Physiologic changes in pregnancy (increased plasma volume, altered protein binding, increased hepatic metabolism) may reduce hydrocortisone levels. Doses may need to be increased, especially in the second and third trimesters. Stress doses should be adjusted for labor and delivery. Individualize based on clinical response and serum cortisol monitoring.
Pregnancy may require dose increase due to altered pharmacokinetics (increased clearance, volume of distribution). However no specific dose adjustment guidelines; use lowest effective dose. Consider stress-dose steroids during labor and delivery for patients on chronic therapy.
Category C
Category C
Hydrocortisone is a short-acting glucocorticoid used for anti-inflammatory and immunosuppressive effects. In adrenal insufficiency, it is the preferred replacement therapy due to its mineralocorticoid activity at higher doses. For acute stress doses (e.g., surgery, trauma), increase to 50-100 mg IV q8h. Monitor serum potassium and glucose regularly. Taper doses to avoid adrenal crisis; do not stop abruptly.
TRIACORT is a synthetic corticosteroid with high glucocorticoid potency and minimal mineralocorticoid activity. It has a long duration of action (36-54 hours) allowing once-daily dosing. Monitor for adrenal suppression during taper; dexamethasone suppression test may require extended sampling. Use cautiously in patients with diabetes, osteoporosis, or peptic ulcer disease. Intra-articular injection can cause post-injection flare; avoid in infected joints.
Take exactly as prescribed; do not stop without consulting your doctor.Report any unusual weight gain, swelling, or severe headaches.Avoid live vaccines during treatment.Carry a medical alert card stating you are on steroid therapy.In case of stress, infection, or surgery, you may need a dose adjustment.
Take exactly as prescribed; do not stop suddenly or adjust dose without consulting your doctor.Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately.Avoid live vaccines while taking this medication.Monitor blood glucose closely if you have diabetes.Carry a medical alert card indicating you are taking corticosteroids.Do not take NSAIDs or aspirin without medical advice due to increased GI bleeding risk.Notify your doctor if you experience vision changes, severe headache, or mood disturbances.